This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ABI-007, nab-paclitaxel, albumin-bound paclitaxel, ABX, paclitaxel albumin-stabilized nanoparticle
Revenue splits are BioMedTracker estimates.
Abraxane combines the active drug paclitaxel with a natural protein called albumin into a nanoparticle 1/100th the size of a red blood cell, avoiding the need for any solvent. Abraxane is the first solvent-free nanoparticle albumin-bound chemotherapeutic, and may potentially exploit an inherent pathway for albumin receptor-mediated transport of drugs across endothelial cell walls of tumor neovasculature.Abraxane was originally developed with the goal of addressing the toxicities associated with the solvents Cremophor-EL and alcohol, used in Taxol. These toxicities required the need to premedicate patients with corticosteroids; required extended infusion times of Taxol; limited the dose of Taxol that could be administered; and, necessitated the use of specialized intravenous tubing sets to avoid leaching of plasticizers into the patient.
ABI and APP Pharmaceuticals
ABI and APPX were strategic partners in the development, manufacture and marketing of Abraxane. ABI was responsible for the clinical development and registration of Abraxane. APP had licensed the exclusive North American manufacturing and marketing rights for Abraxane. In November 2005, the two companies merged to form Abraxis (ABBI).
Taiho and Abraxis
Also in November 2005, Abraxis announced it has licensed Abraxane to Taiho Pharmaceutical and established a Joint Steering Committee with Taiho which will oversee the development of Abraxane in Japan for the treatment of breast, lung, gastric, and other solid tumors. Taiho is part of Otsuka Pharmaceutical Ltd. Under the terms of the license agreement, Abraxis will receive upfront and milestone payments in excess of $50 million, in addition to substantial royalties. Abraxis also will supply Abraxane for the Japanese market.
AstraZeneca and Abraxis
In April 2006, AstraZeneca...See full deal structure in Biomedtracker
Partners: Otsuka Holdings Co., Ltd. Specialised Therapeutics Australia Pty, Ltd.
Additional information available to subscribers only: